2407760-40-9
Chemical Structure
Biological Activity: Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Volrustomig | ≥99.0% | Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Brailey P.M., et al. 288P Volrustomig drives superior CTLA-4 blockade, induces sustained PD-1 degradation, and enhances T cell function ex vivo. Therapeutic Development, 2025, 28(Supplement): 101487.
- [2]. Achour I, et al. Abstract 3627: Volrustomig a novel PD-1/CTLA-4 bispecific antibody leads to robust increase in peripheral and intratumoral pharmacodynamic biomarkers in solid tumors from FTiH study. Cancer Research, 2024, 84(6_Supplement): 3627.
- [3]. Bose CK, et al. Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. J Gynecol Oncol. 2024;35(4):e82. [Content Brief]
- [4]. Tran B, et al. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. Clin Cancer Res. Published online February 17, 2026. [Content Brief]
Keywords
